Alumis INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
ALMS
Alumis INCSCHEDULE: Foresite Capital Adjusts Alumis Stake
Foresite Capital Fund VI LP and related entities have amended their Schedule 13D filing to reflect a disposition of Alumis Inc. common stock.
NASDAQ
ALMS
Alumis INCSCHEDULE: Samsara Funds Boost Alumis Stake to 5.4%
Samsara BioCapital and Opportunity Fund increased their beneficial ownership in Alumis Inc. to 5.4% through recent open market purchases and participation in a public offering.
NASDAQ
ALMS
Alumis INCForesite Capital and its affiliates have updated their beneficial ownership in Alumis Inc. to 14.1% following recent share acquisitions and a follow-on offering.
NASDAQ
ALMS
Alumis INCSamsara BioCapital and its affiliates, including Dr. Srinivas Akkaraju, have increased their beneficial ownership in Alumis Inc. to 5.3% through recent open market purchases.
NASDAQ
ALMS
Alumis INCSamsara BioCapital and related entities have reduced their beneficial ownership in Alumis Inc. to below 5% through recent share sales and transfers.
NASDAQ
ALMS
Alumis INCForesite Capital and its affiliated entities, including James B. Tananbaum, have filed an amended Schedule 13D for Alumis Inc., reporting an aggregate beneficial ownership of 15.9% of common stock, a decrease in percentage due to the Issuer's issuance of additional shares.
NASDAQ
ALMS
Alumis INCSCHEDULE 13D/A: Samsara BioCapital Increases Stake in Alumis Inc. to 5% Following Open Market Purchases and ACELYRIN Merger
Samsara BioCapital, L.P. has increased its beneficial ownership in Alumis Inc. to 5.0%, totaling 4,801,370 shares, through recent open market purchases and shares received from the merger of ACELYRIN, Inc. into Alumis.
NASDAQ
ALMS
Alumis INCSCHEDULE 13D/A: AyurMaya Capital Management Discloses 15.8% Stake in Alumis Inc. Following Merger Completion
AyurMaya Capital Management Company, LP and David E. Goel have disclosed a 15.8% beneficial ownership stake in Alumis Inc. following the completion of a merger where ACELYRIN shares were converted into Alumis common stock.
NASDAQ
ALMS
Alumis INCSCHEDULE 13D/A: Foresite Capital Funds Update Significant Stake in Alumis Inc. Amidst Dilution and New Acquisitions
Foresite Capital and its affiliated entities have filed an amended Schedule 13D, updating their beneficial ownership in Alumis Inc. to reflect a decrease in aggregate percentage due to dilution from new share issuances by Alumis, alongside new acquisitions of common stock by Foresite Capital Fund VI.
NASDAQ
ALMS
Alumis INCAyurMaya Capital Management Company, LP, a significant shareholder in ALUMIS INC., has formally agreed to vote its 22.5% stake in favor of ALUMIS's proposed merger with ACELYRIN, Inc.